The RiskReveal assay was used to determine which early-stage non-squamous NSCLC patients should undergo adjuvant chemotherapy.

The firm touted new assays, provided an update on its nanopore sequencer, and offered insights into upcoming pipeline ...

The London-based firm will provide its CIZ1B lung cancer test and DEX-G2 gastric cancer test for use in Doctors Hospital in the Cayman Islands.

NEW YORK — Genedrive said on Friday that it has received CE marking under the EU's In Vitro Diagnostic Medical Device Regulation (IVDR) for its point-of-care CYP2C19 ID Kit genotyping platform, which ...

NEW YORK – OncoHost, an Israeli biotechnology company, is working with three European medical centers to produce a new flow cytometry test to predict patient response to immunotherapies for five ...

The companies will develop and commercialize diagnostic tools to help clinicians determine which patients would benefit from precision medicine treatments.

Investors and consultants in the space said that they have seen rising enthusiasm among investors as recent funding rounds ...

The company's flagship assay uses whole-genome sequencing to identify patients with high-risk multiple myeloma and determine which patients won't respond to therapies.